Your browser doesn't support JavaScript. Please upgrade to a modern browser or enable JavaScript in your existing browser.
Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Table 2. Overview of high-risk studies1

Factor Carey(39) McDonald(38) Hauth(37) Morales(36) Vermuelen(35)
PTD <37 weeks, placebo 23% 35% 57% 39%  
GA (wk) at treatment 16-23 24 22-24 13-20 26
Treatment Oral metronidazole 2 g, repeat @ 48 hr Oral metronidazole 400 bid, 2 d Oral metronidazole 250 mg tid, 7 days, plus oral erythromycin 333 mg tid, 14 d Oral metronidazole 250 mg tid, 7 d Clindamycin 2% vaginal cream daily, 7 d
Second treatment All, 24-29 wk If positive test, 4 wk post-treatment If positive test, at 28 wk No second treatment All, 32 wk

[1] PTD, preterm delivery; GA, gestational age.

Return to Document

 

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care